Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-cash Items: 2019-2024

Historic Non-cash Items for Tg Therapeutics (TGTX) over the last 6 years, with Dec 2024 value amounting to $3.1 million.

  • Tg Therapeutics' Non-cash Items fell 93.39% to $3.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.1 million, marking a year-over-year decrease of 93.39%. This contributed to the annual value of $3.1 million for FY2024, which is 47.53% up from last year.
  • Per Tg Therapeutics' latest filing, its Non-cash Items stood at $3.1 million for FY2024, which was up 47.53% from $2.1 million recorded in FY2023.
  • Tg Therapeutics' 5-year Non-cash Items high stood at $29.5 million for FY2021, and its period low was $910,625 during FY2020.
  • Moreover, its 3-year median value for Non-cash Items was $2.1 million (2023), whereas its average is $2.5 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 3,139.92% in 2021, then plummeted by 92.86% in 2022.
  • Yearly analysis of 5 years shows Tg Therapeutics' Non-cash Items stood at $910,625 in 2020, then surged by 3,139.92% to $29.5 million in 2021, then plummeted by 92.86% to $2.1 million in 2022, then increased by 1.22% to $2.1 million in 2023, then soared by 47.53% to $3.1 million in 2024.